NCT07158164 2025-11-13
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
Phase 4 Recruiting
Clinical Trials
10 trialsNCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT06217185 2024-02-28
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Hebei Medical University Fourth Hospital
Phase 4 Recruiting
NCT04031885 2021-08-24
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Eli Lilly and Company
Phase 4 Terminated
NCT00812864 2018-08-28
capagec
University Hospital, Limoges
Phase 4 Completed
NCT03465202 2018-03-14
Association of Capecitabine Pharmacokinetics and Toxicity With Aging
Newcastle-upon-Tyne Hospitals NHS Trust
Phase 4 Unknown
NCT02248571 2017-11-13
IMPROVE
iOMEDICO AG
Phase 4 Completed
NCT00087620 2017-02-03
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Hoffmann-La Roche
Phase 4 Terminated
NCT00127933 2011-08-10
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT00121836 2011-04-27
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 4 Completed